Wash U Researchers Use Whole-Genome Sequencing to ID Relapse-Specific Mutations in AML Tumor
May 18, 2010
Wash U Researchers Use Whole-Genome Sequencing to ID Relapse-Specific Mutations in AML Tumor
Elaine Mardis presented preliminary data on the whole-genome sequencing of an AML relapse tumor at last week's Biology of Genomes meeting at Cold Spring Harbor Laboratory.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sequencing of Relapse AML Tumor IDs Mutations in DNMT3A Gene Predictive of Disease Outcome
November 16, 2010 / In Sequence - Illumina Sees Clinical Applications for MiSeq; Plans FDA Submission in 2012
August 3, 2011 / Clinical Sequencing News - IOM Workshop Discusses Interim Strategies to Handle Unresolved Challenges of Clinical Sequencing
July 27, 2011 / Clinical Sequencing News - Sequenom Signs Supply Deal for T21 Test with Illumina; Firms to Collaborate on Regulatory Approval
July 12, 2011 / Clinical Sequencing News - Study Finds Array and Sequencing Combo Yields Novel Info on Gene Expression
June 28, 2011 / In Sequence